TOP TEN perturbations for 1552625_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552625_a_at
Selected probe(set): 222754_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552625_a_at (222754_at) across 6673 perturbations tested by GENEVESTIGATOR:

T-cell isolation study 11 / T-cell isolation study 6

Relative Expression (log2-ratio):-3.954917
Number of Samples:2 / 2
Experimental T-cell isolation study 11
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.
Control T-cell isolation study 6
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.

lactic acid study 1 (hypoxia) / untreated breast epithelial cell sample

Relative Expression (log2-ratio):-3.0324516
Number of Samples:3 / 3
Experimental lactic acid study 1 (hypoxia)
Breast epithelial cells exposed to 25mM lactic acid of pH6.7 and 2% hypoxia. ATC code:
Control untreated breast epithelial cell sample
Breast epithelial cells in control media under normoxia.

expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.756011
Number of Samples:22 / 2
Experimental expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS).
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.5315838
Number of Samples:3 / 2
Experimental expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue obtained from a patient with primary clear cell adenocarcinoma (NOS) of the kidney.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.4397745
Number of Samples:5 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS).
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

tumor supernatant activation study 3 / memory T-cell activation study 1

Relative Expression (log2-ratio):-2.392315
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control memory T-cell activation study 1
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.3904676
Number of Samples:3 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

precursor-B-ALL study 7 (PDX; short-term; <10wk) / precursor-B-ALL study 7 (early relapse; <24m)

Relative Expression (log2-ratio):2.3677845
Number of Samples:5 / 22
Experimental precursor-B-ALL study 7 (PDX; short-term; <10wk)
Leukemia cell samples isolated from spleen of patient derived xenografts (PDX) of precursor B-cell acute lymphoblastic leukemia (B-ALL) generated in NOD/SCID mice with time to manifestation of leukemia (TTL) less than 10 weeks (short-term). Cell suspensions containing more than 90% leukemia cells as estimated by flow cytometry were prepared from infiltrated spleens of leukemia bearing mice. Briefly, unconditioned NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice with a median age of 10 weeks were transplanted by injection of patient leukemia cells, which were isolated from bone marrow or peripheral blood of pediatric patients with BCP-ALL, into the lateral tail vein. Upon clear evidence for leukemia related morbidity, mice were killed and autopsy was performed. Leukemia was confirmed detecting leukemia cells in bone marrow, spleen and peripheral blood. Time to leukemia (TTL) was determined as weeks from transplant to clinical leukemia manifestation. Donor characteristics: 3 females and 9 males; 1-9 years old; good response to prednison; no fusion gene,;remision at day 33; non-high risk group; early relapse group (relapse within 24 months from diagnosis).
Control precursor-B-ALL study 7 (early relapse; <24m)
Leukemia cell samples isolated from bone marrow of pediatric patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) with relapse within 24 months after diagnosis (early relapse). White blood cells were isolated through Ficoll-Hypaque density gradient centrifugation. All diagnostic leukemia samples were obtained before treatment from pediatric de novo B cell precursor ALL patients (BCP-ALL). Samples obtained from studies registred under NCT00430118 and NCT00613457.

expO kidney cancer study 1 (renal cell carcinoma, chromophobe type; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.2708454
Number of Samples:18 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, chromophobe type; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, chromophobe type.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (neuroendocrine carcinoma; primary)

Relative Expression (log2-ratio):2.2429028
Number of Samples:2 / 6
Experimental expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS).
Control expO lung cancer study 1 (neuroendocrine carcinoma; primary)
Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma.